Back to Search
Start Over
A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.
- Source :
-
Clinical pharmacokinetics [Clin Pharmacokinet] 2018 Nov; Vol. 57 (11), pp. 1459-1469. - Publication Year :
- 2018
-
Abstract
- Background and Objective: Intracellular exposure of everolimus may be a better marker of therapeutic effect than trough whole blood concentrations. We aimed to develop pharmacokinetic population models and Bayesian estimators based on a limited sampling strategy for estimation of dose interval exposures of everolimus in whole blood and peripheral blood mononuclear cells (PBMCs) in renal transplant recipients.<br />Methods: Full whole blood and PBMC concentration-time profiles of everolimus were obtained from 12 stable renal transplant recipients on two different occasions, 4 weeks apart. The dataset was treated as 24 individual profiles and split into a development dataset (n = 20) and a validation dataset (n = 4). The pharmacokinetic model was developed using non-parametric modeling and its performances and those of the derived Bayesian estimator were evaluated in the validation set.<br />Results: A structural two-compartment model with first-order elimination and two absorption phases described by a sum of two gamma distributions were developed. None of the tested covariates (age, sex, albumin, hematocrit, fat-free mass and genetic variants such as CYP3A5*1, ABCB1 haplotype, PPARA*42, PPARA*48, and POR*28) were retained in the final model. A limited sampling schedule of two whole blood samples at 0 and 1.5 h and one PBMC sample at 1.5 h post dose provided accurate estimates of the area under the plasma concentration-time curve (AUC) in comparison with the trapezoidal reference AUC (relative bias ± standard deviation = - 3.9 ± 10.6 and 4.1 ± 12.3% for whole blood and PBMC concentrations, respectively).<br />Conclusion: The developed model allows simultaneous and accurate prediction of everolimus exposure in whole blood and PBMCs, and supplies a base for a feasible exploration of the relationships between intracellular exposure and therapeutic effects in prospective trials.
- Subjects :
- ATP Binding Cassette Transporter, Subfamily B genetics
Adult
Aged
Bayes Theorem
Biological Availability
Cytochrome P-450 CYP3A genetics
Cytochrome P-450 Enzyme System genetics
Female
Genotype
Humans
Immunosuppressive Agents blood
Immunosuppressive Agents pharmacokinetics
Male
Middle Aged
Models, Biological
PPAR alpha genetics
Transplant Recipients
Everolimus blood
Everolimus pharmacokinetics
Kidney Transplantation methods
Leukocytes, Mononuclear metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1926
- Volume :
- 57
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Clinical pharmacokinetics
- Publication Type :
- Academic Journal
- Accession number :
- 29556934
- Full Text :
- https://doi.org/10.1007/s40262-018-0646-5